Kronos Bio, Inc (KRON)

Etorro trading 970x250

About Kronos Bio, Inc

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California. Address: 1300 South El Camino Real, San Mateo, CA, United States, 94402

Kronos Bio, Inc News and around…

Latest news about Kronos Bio, Inc (KRON) common stock and company :

Analysts Predict 16% Gains Ahead For The Holdings of VTWV
19 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $168.64 per unit.

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Kronos Bio Enters Oversold Territory (KRON)
11 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Is Kronos Bio, Inc.'s (NASDAQ:KRON) Shareholder Ownership Skewed Towards Insiders?
11 Oct, 2021 Yahoo! Finance

A look at the shareholders of Kronos Bio, Inc. ( NASDAQ:KRON ) can tell us which group is most powerful. Institutions...

Chief Scientific Officer Of Kronos Bio Trades $220K In Company Stock
05 Oct, 2021 Yahoo! Finance

Christopher Dinsmore, Chief Scientific Officer at Kronos Bio (NASDAQ:KRON), made a large buy and sell of company shares on October 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Christopher Dinsmore exercised options to purchase 9,189 Kronos Bio shares at a price of $3.27 per share for a total of $30,048 on October 4. They then sold their shares on the same day in the open market. They sold at a price of $20.81 to rai

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
30 Sep, 2021 FinancialContent

Preliminary clinical data from Phase 1/2 study still anticipated in Q4

Add Up The Pieces: VBK Could Be Worth $337
17 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $336.54 per unit.

Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations
14 Sep, 2021 FinancialContent
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference 
07 Sep, 2021 FinancialContent
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
07 Sep, 2021 Yahoo! Finance

SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13th at 7 a.m. ET. The fireside chat will be webcast live from the Investors & Media section of the company’s website at www.kronosbio.com. A re

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Add Up The Pieces: VBK Could Be Worth $333
16 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $332.65 per unit.

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results
12 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Is Kronos Bio, Inc. (KRON) A Good Stock To Buy?
27 Jul, 2021 Yahoo! Finance

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
27 Jul, 2021 FinancialContent
Implied VBK Analyst Target Price: $325
13 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $324.76 per unit.

Have Insiders Been Buying Kronos Bio, Inc. (NASDAQ:KRON) Shares This Year?
12 Jul, 2021 Yahoo! Finance

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021
24 Jun, 2021 FinancialContent

Upgrades Zelman upgraded the previous rating for Armstrong World Industries Inc (NYSE:AWI) from Hold to Buy. For the ...

Kronos Bio Announces Participation in Upcoming Investor Conferences
26 May, 2021 FinancialContent
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today
25 May, 2021 FinancialContent
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day
11 May, 2021 FinancialContent
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference
06 May, 2021 FinancialContent
12 Health Care Stocks Moving In Tuesday's Intraday Session
27 Apr, 2021 FinancialContent

Gainers Vaxart (NASDAQ:VXRT) shares moved upwards by 53.38% to $9.29 during Tuesday's regular session. Vaxart's ...

The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
21 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex
20 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Friday
16 Apr, 2021 FinancialContent

Before 10 a.m. ET Friday, 62 stocks made new 52-week lows. Significant Points: The largest company by ...

The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
16 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
15 Apr, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Kronos Bio, Inc (KRON) is a NASDAQ Common Stock listed in ,

970x250